RECOVERY Trial
University of Oxford
  • Site Map
  • Accessibility
  • Cookies
  • Log in
  • Home
  • For patients
  • For Site Staff
  • Results
  • News
  1. Results
  2. Study Protocol Archive

Study Protocol  & Statistical Analysis Plan Archive

RECOVERY protocol v1.0 (2020-03-18)

RECOVERY protocol v2.0 (2020-03-23)

RECOVERY protocol v3.0 (2020-04-07)

RECOVERY protocol v4.0 (2020-04-14)

RECOVERY protocol v5.0 (2020-04-24)

RECOVERY protocol v6.0 (2020-05-14)

RECOVERY protocol v7.0 (2020-06-18)

RECOVERY protocol v8.0 (2020-07-08)

RECOVERY protocol v.9.1 (2020-09-18)

RECOVERY protocol v10.1 (2020-11-01)

Statistical Analysis Plan v1 (published 9 June 2020)

Statistical Analysis Plan v1.1 (published 22 June 2020)


Definition and Derivation of Baseline Characteristics and Outcomes  (published 9 June 2020)

Definition and Derivation of Baseline Characteristics and Outcomes v2 (published 11 Dec 2020)


 


© 2021 Nuffield Department of Population Health
  • Freedom of Information
  • Privacy Policy
  • Copyright Statement
  • Site Map
  • Accessibility
  • Cookies
  • Log in
powered by Haiku
  • For patients
    • Why is this research being done?
    • What is the purpose of this study?
    • Who is doing the study?
    • Who is being included in the study?
    • What happens next if I agree to be included in this study?
    • What are the possible benefits of being in the study?
    • What are the possible risks of being in the study?
    • Can I stop the study treatment or my participation early?
    • If I have any questions or problems, who can I call?
    • What information do you hold about me and how do you keep it private?
    • Do I have to take part?
    • Are there any financial costs or payments?
    • What else can you tell me?
    • What about my data privacy?
    • Videos
    • RECOVERY trial participant newsletter sign-up
    • RECOVERY trial participant newsletter opt-out
    • RECOVERY trial participant newsletter sign-up
    • RECOVERY trial participant newsletter opt-out
  • For Site Staff
    • Pharmacy
    • Site Set-Up
      • RECOVERY Trial FAQs for sites
      • Data Monitoring Committee correspondence
      • Regulatory documents
    • Training
      • Background and informed consent
      • 1st and 2nd randomisation
      • Children and neonates
      • Convalescent plasma and monoclonal antibodies
      • Follow-up
      • Oral Therapies
    • site teams
    • Follow-up data collection
    • Randomisation
    • Randomisation Training Confirmation
    • Background & Consent Training Confirmation
    • Children & Neonates Training Confirmation
    • Convalescent Plasma Training Confirmation
    • Monoclonal Antibodies Training Confirmation
    • Oral Therapies Training Confirmation
    • Follow-up Training Confirmation
  • Results
    • Dexamethasone results
    • Hydroxychloroquine results
    • Lopinavir-Ritonavir results
    • Study Protocol Archive
    • Azithromycin results
  • News
    • Oxford's COVID-19 research receives government funding
    • First patients enrolled in new clinical trial of possible COVID-19 treatments
    • Letter from Chief Medical Officers encourages participation in COVID-19 trials
    • RECOVERY Trial rolled out across the UK
    • RECOVERY team reflect on International Clinical Trials Day 2020
    • Recruitment to the RECOVERY Trial continues as planned
    • First patient, a child, receives convalescent plasma through RECOVERY, the dedicated COVID-19 treatment trial
    • No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
    • Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
    • No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY
    • RECOVERY COVID-19 phase 3 trial to evaluate Regeneron’s REGN-COV2 investigational antibody cocktail in the UK
    • Lopinavir-ritonavir is not an effective treatment for patients hospitalised with COVID-19
    • RECOVERY trial management acknowledged in clinical trial awards
    • Statement on Regeneron’s pause in recruitment to a REGN-COV2 antibody cocktail trial
    • Update on Regeneron’s pause in recruitment to a REGN-COV2 antibody cocktail trial
    • Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
    • RECOVERY participant is first person to receive and donate convalescent plasma
    • RECOVERY trial clinicians can now be accredited through the Associate Principal Investigator Scheme
    • Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
    • RECOVERY trial shortlisted for the National Project Awards 2020 Special COVID-19 response category
    • RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19
    • Leicester’s hospitals recruit over 1,000 patients for the RECOVERY trial
    • Update on recruitment to convalescent plasma and tocilizumab treatment arms
    • RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19